beta-cell function and anti-diabetic pharmacotherapy (Q36947018)

17 August 2017

1 reference

title

beta-cell function and anti-diabetic pharmacotherapy (English)

1 reference

17 August 2017

0 references

0 references

Stefano Del Prato

1

1 reference

PubMed ID

17883249

17 August 2017

Cristina Bianchi

series ordinal

2

1 reference

PubMed ID

17883249

17 August 2017

Piero Marchetti

series ordinal

3

1 reference

17 August 2017

1 October 2007

1 reference

Diabetes - Metabolism: Research and Reviews

17 August 2017

1 reference

17 August 2017

23

1 reference

17 August 2017

7

1 reference

17 August 2017

518-527

1 reference

Coping with Type II diabetes: the patient's perspective.

17 August 2017

1 reference

Revealing the cost of Type II diabetes in Europe.

21 January 2018

1 reference

7 January 2021

Management of dyslipidemia in children and adolescents with diabetes

1 reference

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

7 January 2021

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

7 January 2021

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

7 January 2021

Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk)

1 reference

7 January 2021

Standards of medical care in diabetes

1 reference

7 January 2021

Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study.

1 reference

7 January 2021

Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development

1 reference

7 January 2021

Deteriorating beta-cell function in type 2 diabetes: a long-term model

1 reference

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

7 January 2021

Phasic insulin release and metabolic regulation in type 2 diabetes.

1 reference

7 January 2021

Assessment of beta-cell function during the oral glucose tolerance test by a minimal model of insulin secretion.

1 reference

7 January 2021

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

1 reference

7 January 2021

Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study

1 reference

7 January 2021

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

7 January 2021

Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration

1 reference

7 January 2021

Sulfonylurea induced beta-cell apoptosis in cultured human islets

1 reference

7 January 2021

Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets

1 reference

7 January 2021

Functional and molecular defects of pancreatic islets in human type 2 diabetes

1 reference

7 January 2021

Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose

1 reference

7 January 2021

Selective unresponsiveness of pancreatic beta-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM

1 reference

7 January 2021

Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin.

1 reference

7 January 2021

Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells

1 reference

7 January 2021

Lipotoxicity in human pancreatic islets and the protective effect of metformin

1 reference

7 January 2021

The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose

1 reference

7 January 2021

Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion

1 reference

7 January 2021

Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus.

1 reference

7 January 2021

Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin

1 reference

7 January 2021

Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes

1 reference

7 January 2021

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

1 reference

7 January 2021

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

1 reference

7 January 2021

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

7 January 2021

Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes

1 reference

7 January 2021

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

1 reference

7 January 2021

Long-term glycaemic control with pioglitazone in patients with type 2 diabetes

1 reference

7 January 2021

An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.

1 reference

7 January 2021

Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus.

1 reference

7 January 2021

Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.

1 reference

7 January 2021

beta-cell deterioration - prospects for reversal or prevention

1 reference

7 January 2021

Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.

1 reference

7 January 2021

Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress

1 reference

7 January 2021

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

1 reference

7 January 2021

Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance

1 reference

7 January 2021

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance

1 reference

7 January 2021

The DREAM trial – Authors' reply

1 reference

7 January 2021

Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes

1 reference

7 January 2021

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

1 reference

7 January 2021

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

7 January 2021

The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

1 reference

7 January 2021

Effect of acarbose on insulin sensitivity in elderly patients with diabetes.

1 reference

7 January 2021

Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance

1 reference

7 January 2021

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

1 reference

7 January 2021

Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study

1 reference

7 January 2021

Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve

1 reference

7 January 2021

Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose)

1 reference

7 January 2021

Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.

1 reference

7 January 2021

alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients

1 reference

7 January 2021

Overview of incretin hormones

1 reference

7 January 2021

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

7 January 2021

Mechanisms of action of glucagon-like peptide 1 in the pancreas

1 reference

7 January 2021

beta-cell failure in diabetes and preservation by clinical treatment

1 reference

7 January 2021

Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes

1 reference

7 January 2021

Circulation and degradation of GIP and GLP-1.

1 reference

7 January 2021

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

7 January 2021

1 reference

7 January 2021

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

7 January 2021

Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties

1 reference

7 January 2021

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

1 reference

7 January 2021

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

1 reference

7 January 2021

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

1 reference

7 January 2021

The role of GLP-1 in the life and death of pancreatic beta cells.

1 reference

7 January 2021

Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function

1 reference

7 January 2021

Phosphorylation-dependent nucleocytoplasmic shuttling of pancreatic duodenal homeobox-1.

1 reference

7 January 2021

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

1 reference

7 January 2021

Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats

1 reference

7 January 2021

Glucagon-like peptide-1.

1 reference

7 January 2021

Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells

1 reference

7 January 2021

Minireview: the glucagon-like peptides

1 reference

7 January 2021

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

1 reference

7 January 2021

Beta-cell function improved by supplementing basal insulin secretion in mild diabetes

1 reference

7 January 2021

Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal

1 reference

7 January 2021

Induction of Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients by Transient Intensive Insulin Treatment

1 reference

7 January 2021

Short-term intensive insulin therapy in newly diagnosed type 2 diabetes

1 reference

7 January 2021

Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients

1 reference

7 January 2021

Disruption of IRS-2 causes type 2 diabetes in mice

1 reference

7 January 2021

Endocrine pancreas plasticity under physiological and pathological conditions

1 reference

7 January 2021

Adenosine 5'-triphosphate-sensitive potassium channels

1 reference

7 January 2021

Roles of ATP-sensitive K+ channels in cell survival and differentiation in the endocrine pancreas

1 reference

7 January 2021

Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes

1 reference

7 January 2021

Beta cell rest and recovery--does it bring patients with latent autoimmune diabetes in adults to euglycemia?

1 reference

7 January 2021

Transgenic overexpression of hepatocyte growth factor in the beta-cell markedly improves islet function and islet transplant outcomes in mice

1 reference

7 January 2021

Targeted expression of placental lactogen in the beta cells of transgenic mice results in beta cell proliferation, islet mass augmentation, and hypoglycemia.

1 reference

7 January 2021

Overexpression of parathyroid hormone-related protein inhibits pancreatic beta-cell death in vivo and in vitro

1 reference

7 January 2021

A kinase in the life of the beta cell

1 reference

7 January 2021

Treatment issues in type 2 diabetes

1 reference

7 January 2021

New drug targets for type 2 diabetes and the metabolic syndrome

1 reference

7 January 2021

Activation of IRS-2-mediated signal transduction by IGF-1, but not TGF-alpha or EGF, augments pancreatic beta-cell proliferation

1 reference

7 January 2021

Tweaking the glucose sensor: adjusting glucokinase activity with activator compounds

1 reference

7 January 2021

Beta-cell mass plasticity in type 2 diabetes.

1 reference

7 January 2021

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

7 January 2021

Metformin monotherapy for type 2 diabetes mellitus

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD002966.PUB3

Identifiers

DOI

10.1002/DMRR.770

1 reference

17 August 2017

1 reference

PubMed ID

17883249